Mabpharm Limited

SEHK:2181 Stock Report

Market Cap: HK$1.8b

Mabpharm Balance Sheet Health

Financial Health criteria checks 2/6

Mabpharm has a total shareholder equity of CN¥88.9M and total debt of CN¥264.1M, which brings its debt-to-equity ratio to 297%. Its total assets and total liabilities are CN¥1.0B and CN¥927.3M respectively.

Key information

297.0%

Debt to equity ratio

CN¥264.09m

Debt

Interest coverage ration/a
CashCN¥89.34m
EquityCN¥88.93m
Total liabilitiesCN¥927.28m
Total assetsCN¥1.02b

Recent financial health updates

Is Mabpharm (HKG:2181) Using Too Much Debt?

Mar 27
Is Mabpharm (HKG:2181) Using Too Much Debt?

Mabpharm (HKG:2181) Is Making Moderate Use Of Debt

Oct 20
Mabpharm (HKG:2181) Is Making Moderate Use Of Debt

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Jan 18
Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Oct 07
Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Apr 28
Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

Jan 27
We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

Recent updates

Is Mabpharm (HKG:2181) Using Too Much Debt?

Mar 27
Is Mabpharm (HKG:2181) Using Too Much Debt?

There's Reason For Concern Over Mabpharm Limited's (HKG:2181) Massive 45% Price Jump

Feb 19
There's Reason For Concern Over Mabpharm Limited's (HKG:2181) Massive 45% Price Jump

Investors Don't See Light At End Of Mabpharm Limited's (HKG:2181) Tunnel

Dec 22
Investors Don't See Light At End Of Mabpharm Limited's (HKG:2181) Tunnel

Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

Jun 14
Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%

Jan 24
More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%

Mabpharm (HKG:2181) Is Making Moderate Use Of Debt

Oct 20
Mabpharm (HKG:2181) Is Making Moderate Use Of Debt

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Jan 18
Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Oct 07
Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Apr 28
Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?

Mar 03
Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?

We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

Jan 27
We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?

Dec 09
Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?

Financial Position Analysis

Short Term Liabilities: 2181's short term assets (CN¥365.8M) exceed its short term liabilities (CN¥312.1M).

Long Term Liabilities: 2181's short term assets (CN¥365.8M) do not cover its long term liabilities (CN¥615.2M).

Debt to Equity History and Analysis

Debt Level: 2181's net debt to equity ratio (196.5%) is considered high.

Reducing Debt: 2181's debt to equity ratio has increased from 6.2% to 297% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 2181 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 2181 has less than a year of cash runway if free cash flow continues to grow at historical rates of 20.1% each year.

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/07 02:13
End of Day Share Price 2025/05/07 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mabpharm Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yue-Kwong LuiJefferies LLC